PROphylactic Manual RotatIon in the Second stagE of Labor (PROMISE)

March 24, 2024 updated by: Stephanie Fisher, Northwestern University

PROphylactic Manual RotatIon in the Second stagE of Labor (PROMISE): a Randomized Controlled Trial

This is a randomized controlled trial to determine whether prophylactic manual rotation for fetuses identified to have persistent occiput posterior or occiput transverse presentation (POP/OTP) at the initiation of the second stage of labor in nulliparous individuals reduces rates of operative delivery, second stage of labor duration, and resultant adverse clinical outcomes compared to standard management of the second stage of labor.

Study Overview

Detailed Description

This is a randomized controlled trial in which nulliparous individuals with a term, singleton gestation who undergo a trial of labor with neuraxial anesthesia and have a fetus presenting with persistent occiput posterior or occiput transverse presentation (POP/OTP) confirmed by ultrasound at the initiation of the second stage of labor will be randomized to either prophylactic manual rotation or sham rotation. The study aims to evaluate whether prophylactic manual rotation reduces the incidence of operative delivery (a composite of cesarean and operative vaginal delivery), second stage of labor duration, and maternal and neonatal morbidity among nulliparous individuals with a fetus with POP/OTP at the initiation of the second stage of labor.

Individuals will be screened for eligibility upon admission to Labor and Delivery and approached for potential recruitment with informed consent obtained on enrollment. Once women achieve complete cervical dilation and within the first fifteen minutes of commencement of pushing, a bedside ultrasound will be performed to determine the fetal position. Those with POP/OTP will be randomized at that time point to either prophylactic manual rotation or sham rotation. The patient's primary obstetrician will be blinded to the randomization arm. The electronic health record will be reviewed and used to assess trial outcomes. The study will enroll 350 individuals, powered to detect a 15% reduction in operative delivery (instrumental vaginal delivery or cesarean section) with prophylactic manual rotation of POP/OTP, from a baseline risk of 50% without manual rotation to 35% with prophylactic rotation at initiation of the second stage of labor.

Study Type

Interventional

Enrollment (Actual)

42

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Illinois
      • Chicago, Illinois, United States, 60657
        • Northwestern Memorial Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Pregnant
  • Age 18 years or greater
  • English-speaking
  • Nulliparous
  • Singleton gestation
  • Planning a vaginal birth
  • Have neuraxial anesthesia
  • Term gestation (≥37 weeks' gestation)
  • Ruptured membranes
  • Complete cervical dilation
  • Cephalic presenting fetus
  • Fetus presenting with occiput posterior or occiput transverse position confirmed by ultrasound

Exclusion Criteria:

  • Pregnancies with intrauterine fetal demise
  • Pregnancies affected by major fetal anomaly
  • Maternal or fetal contraindication to vaginal delivery, including operative vaginal delivery
  • Fetal malpresentation, including brow or face presentation
  • Category III fetal heart rate tracing at time of randomization
  • Duration of pushing already exceeding 15 minutes in the second stage of labor
  • Lack of other inclusion criteria as described above

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Prophylactic manual rotation
Prophylactic manual rotation involves a vaginal examination performed with an obstetric provider's hands to turn the baby from a position in which the baby's face is looking up in the direction of the ceiling (occiput posterior) or to the side (occiput transverse) to a position in which the baby's face is looking down in the direction of the mother's spine (occiput anterior). Prophylactic manual rotation will occur at the initiation of pushing once the individual achieves complete cervical dilation.
Prophylactic manual rotation, performed in the experimental arm, involves a vaginal examination performed with an obstetric provider's hands to turn the baby from a position in which the baby's face is looking up in the direction of the ceiling (occiput posterior) or to the side (occiput transverse) to a position in which the baby's face is looking down in the direction of the mother's spine (occiput anterior). Prophylactic manual rotation will occur at the initiation of pushing once the individual achieves complete cervical dilation, performed by a trained study investigator (M.D. or midwife) to maintain blinding of the patient's primary obstetrician.
Sham Comparator: Sham rotation
Sham rotation involves a vaginal exam that obstetric providers commonly do with their hands to assess cervical dilation and fetal position during routine labor, and will occur at the initiation of pushing once the individual achieves complete cervical dilation.
Sham rotation, performed in the comparator arm, involves a vaginal exam that obstetric providers commonly do with their hands to assess cervical dilation and fetal position during routine labor, and will occur at the initiation of pushing once the individual achieves complete cervical dilation. Duration of the vaginal exam for sham rotation will be consistent with that used for prophylactic manual rotation and will be performed by a trained study investigator (M.D. or midwife) to maintain blinding of the patient's primary obstetrician.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of participants in each group who undergo operative delivery
Time Frame: From randomization until delivery, up to 5 hours
Number of participants in each group who undergo a cesarean section or an instrumental delivery (vacuum or forceps) as a composite outcome
From randomization until delivery, up to 5 hours

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of participants in each group who undergo operative vaginal delivery
Time Frame: From randomization until delivery, up to 5 hours
Number of participants in each group who undergo an instrumental vaginal delivery with vacuum or forceps
From randomization until delivery, up to 5 hours
Number of participants in each group who undergo cesarean delivery
Time Frame: From randomization until delivery, up to 5 hours
Number of participants in each group who undergo a cesarean section
From randomization until delivery, up to 5 hours
Number of minutes in the second stage of labor in each group
Time Frame: From randomization until delivery, up to 300 minutes
Number of minutes participants in each group spend in the second stage of labor
From randomization until delivery, up to 300 minutes
Number of participants in each group with composite maternal morbidity
Time Frame: From randomization until hospital discharge, an expected average of 3 days
Number of participants in each group with a composite of the following individual adverse maternal outcomes: obstetric anal sphincter injury (i.e. 3rd or 4th degree perineal lacerations), postpartum hemorrhage (i.e. estimated blood loss as defined by >1000ml), blood product transfusion, intrapartum chorioamnionitis diagnosed in the second stage of labor, or postpartum endometritis
From randomization until hospital discharge, an expected average of 3 days
Number of participants in each group with maternal intrapartum chorioamnionitis diagnosed in the second stage of labor
Time Frame: From randomization until delivery, up to 5 hours
Number of participants in each group who are diagnosed with intrapartum chorioamnionitis during the second stage of labor as defined by fever greater than 100.4 Fahrenheit in the intrapartum period and at least one additional clinical factor (fundal tenderness, maternal tachycardia, fetal tachycardia, or purulent discharge) with initiation of a therapeutic antibiotic regimen in the second stage of labor
From randomization until delivery, up to 5 hours
Number of participants in each group with postpartum endometritis
Time Frame: From delivery until hospital discharge, an expected average of 3 days
Number of participants in each group who experience postpartum endometritis as defined by fever greater than 100.4 Fahrenheit and one additional clinical factor (fundal tenderness or purulent lochia) in the postpartum period with the initiation of a therapeutic antibiotic regimen in the postpartum period
From delivery until hospital discharge, an expected average of 3 days
Number of participants in each group with postpartum hemorrhage
Time Frame: From randomization until hospital discharge, an expected average of 3 days
Number of participants in each group with postpartum hemorrhage (i.e. estimated blood loss as defined by >1000ml)
From randomization until hospital discharge, an expected average of 3 days
Number of participants in each group who require blood product transfusion
Time Frame: From randomization until hospital discharge, an expected average of 3 days
Number of participants in each group who require blood product transfusion
From randomization until hospital discharge, an expected average of 3 days
Number of participants in each group who experience obstetric anal sphincter injury (i.e. a composite of 3rd or 4th degree perineal lacerations)
Time Frame: From randomization until delivery, up to 5 hours
Number of participants in each group with 3rd or 4th degree perineal lacerations as a composite outcome
From randomization until delivery, up to 5 hours
Number of participants in each group with composite severe neonatal morbidity
Time Frame: From delivery until hospital discharge, up to 28 days of life
Number of participants in each group with neonates with the composite of the following individual adverse neonatal outcomes: 5-minute Apgar score <5, arterial cord pH ≤7.00 or base excess ≤-12 milliequivalents/L, shoulder dystocia, hypoxic-ischemic encephalopathy requiring hypothermic therapy or neonatal subgaleal or intracranial hemorrhage, neonatal intensive care unit (NICU) admission, or neonatal sepsis
From delivery until hospital discharge, up to 28 days of life
Number of participants in each group who experience neonatal death
Time Frame: From delivery until hospital discharge, up to 28 days of life
Number of participants in each group with neonates who experience neonatal death after delivery prior to hospital discharge
From delivery until hospital discharge, up to 28 days of life
Number of participants in each group affected by neonatal intensive care unit (NICU) admission
Time Frame: From delivery until hospital discharge, up to 28 days of life
Number of participants in each group with a neonate that requires neonatal intensive care unit (NICU) admission following delivery
From delivery until hospital discharge, up to 28 days of life
Number of days a participant in each group has a neonate requiring neonatal intensive care unit (NICU) admission
Time Frame: From delivery until hospital discharge, up to 28 days of life
Number of days a participant in each group has a neonate that is admitted to the neonatal intensive care unit (NICU) following delivery
From delivery until hospital discharge, up to 28 days of life
Number of participants in each group with a neonate with neonatal 5-minute Apgar score <5
Time Frame: From delivery up to 5 minutes of life
Number of participants in each group with a neonate that has an Apgar score less than 5 at 5 minutes of life
From delivery up to 5 minutes of life
Number of participants in each group with a neonate with neonatal umbilical arterial cord pH ≤7.00 or base excess ≤-12 milliequivalents/L
Time Frame: At time of delivery
Number of participants in each group with a neonate that has an umbilical arterial cord pH less than or equal to 7.00 or base excess less than or equal to -12 milliequivalents/L as a composite outcome
At time of delivery
Number of participants in each group who experiences intrapartum shoulder dystocia
Time Frame: From randomization until delivery, up to 5 hours
Number of participants in each group that experiences a shoulder dystocia at delivery
From randomization until delivery, up to 5 hours
Number of participants in each group with a neonate with neonatal hypoxic-ischemic encephalopathy requiring hypothermic therapy or neonatal subgaleal or intracranial hemorrhage
Time Frame: From delivery until hospital discharge, up to 28 days of life
Number of participants in each group with a neonate that experiences development of hypoxic-ischemic encephalopathy requiring hypothermic therapy or development of subgaleal or intracranial hemorrhage as a result of birth trauma or other delivery event
From delivery until hospital discharge, up to 28 days of life
Number of participants in each group with a neonate with neonatal sepsis
Time Frame: From delivery until hospital discharge, up to 28 days of life
Number of participants in each group with a neonate that experiences neonatal sepsis as defined by pathogenic bacterial infection confirmed in blood or cerebrospinal fluid culture
From delivery until hospital discharge, up to 28 days of life

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Stephanie Fisher, MD MPH, Northwestern University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 4, 2022

Primary Completion (Actual)

December 15, 2023

Study Completion (Actual)

December 15, 2023

Study Registration Dates

First Submitted

November 8, 2021

First Submitted That Met QC Criteria

December 30, 2021

First Posted (Actual)

January 3, 2022

Study Record Updates

Last Update Posted (Actual)

March 26, 2024

Last Update Submitted That Met QC Criteria

March 24, 2024

Last Verified

March 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pregnancy Related

Clinical Trials on Prophylactic manual rotation

Subscribe